Abstract：OBJECTIVE: To bioinformatically predict and analyze target genes of miRNA-126*, with the aim of providing certain basis for related research about target genes and regulatory mechanism in the future. METHODS: The miRNA chip technology was applied to measure expression levels of miRNA-126* in 3 time points (embryo 16, 19 and 21 days) of fetal lung development. Then the target genes of miRNA-126* were screened through miRGen2.0 database. Subsequent bioinformatic analysis of these target genes was performed by Gene Ontology analysis and Kyoto Encyclopedia of Genes and Genomes Pathway analysis (KEGG Pathway analysis). RESULTS: miRNA-126* manifested continuously upregulated expression with the lung development (from embryo 16 to 21 days). There were 422 predicted target genes in total, and the gene set mainly located in glucuronosyltransferase activity, transferase activity (GO molecular function), multicellular organismal development, developmental process (GO biology process) and intracellular part (GO cellular component). The KEGG Pathway analysis demonstrated that the gene set mostly located in RNA degradation (signal transduction pathway) and prion diseases (disease pathway). CONCLUSIONS: The results suggest that miRNA-126* plays a certain role in fetal lung development and provide a basis for lung devlopment research in the future.
YANG Yang,KAN Qing,ZHANG Pan et al. Bioinformatic analysis of target gene P rediction and related signaling pathways of miRNA-126*[J]. CJCP, 2013, 15(3): 227-232.
［2］Croce CM, Calin GA. miRNAs, cancer, and stem cell division［J］. Cell, 2005, 122(1): 6-7.
［3］Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact［J］. J Clin Oncol, 2009, 27(34): 5848-5856.
［4］Stefani G, Slack FJ. Small non-coding RNAs in animal development［J］. Nat Rev Mol Cell Biol, 2008, 9(3): 219-230.
［5］Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL. Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells［J］. Dev Biol, 2007, 310(2): 442-453.
［6］Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells［J］. Cancer Res, 2007, 67(16): 7713-7722.
［7］Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation［J］. Nature, 2004, 428(6984): 754-758.
［8］Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity［J］. Dev Cell, 2008, 15(2): 272-284.
［9］Alexiou P, Vergoulis T, Gleditzsch M, Prekas G, Dalamagas T, Megraw M, et al. miRGen 2.0: a database of microRNA genomic information and regulation［J］. Nucleic Acids Res, 2010, 38(Database issue): D137-D141.
［11］Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells［J］. Biochem Biophys Res Commun, 2009, 379(3): 726-731.
［12］Meister J, Schmidt MH. miR-126 and miR-126*: new players in cancer［J］. Sci World J, 2010, 10: 2090-2100.
